^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    SYNE1 mutation

    i
    Other names: SYNE1, Spectrin Repeat Containing Nuclear Envelope Protein 1, Myocyte Nuclear Envelope Protein 1, Nesprin-1, Enaptin, MYNE1, Spectrin Repeat Containing, Nuclear Envelope 1, Synaptic Nuclear Envelope Protein 1, KASH Domain-Containing Protein 1, DJ45H2.2, KIAA0796, C6orf98, ARCA1, KASH1, Nesp1, SCAR8, CPG2, 8B, Nuclear Envelope Spectrin Repeat Protein 1, Nuclear Envelope Spectrin Repeat-1, Chromosome 6 Open Reading Frame 98, Synaptic Nuclei Expressed Gene 1, CPG2 Full Length, Nesprin 1, KIAA1262,
    Entrez ID:
    23345
    2ms
    Nesprin1 deficiency is associated with poor prognosis of renal cell carcinoma and resistance to sunitinib treatment. (PubMed, Oncology)
    The results indicate that the expression of SYNE1/Nesprin1 and SYNE1 mutations in patients with RCC are closely linked to their prognosis and responsiveness to sunitinib treatment.
    Journal
    |
    SYNE1 (Spectrin Repeat Containing Nuclear Envelope Protein 1)
    |
    SYNE1 mutation
    |
    sunitinib
    3ms
    Clinical and genetic factors associated with tumor response to neoadjuvant (chemo)radiotherapy, survival and recurrence risk in rectal cancer. (PubMed, Int J Cancer)
    By uncovering factors impacting CR, OS, and TTR, this study underscores the importance of tailored approaches for rectal cancer patients. These findings, based on extensive analysis and mutation data, pave the way for personalized interventions, optimizing outcomes in the challenges of rectal cancer preoperative treatment.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • SMAD4 (SMAD family member 4) • CEACAM5 (CEA Cell Adhesion Molecule 5) • APC (APC Regulator Of WNT Signaling Pathway) • SYNE1 (Spectrin Repeat Containing Nuclear Envelope Protein 1)
    |
    KRAS mutation • BRAF mutation • APC mutation • SYNE1 mutation
    7ms
    SYNE1 Mutation Is Associated with Increased Tumor Mutation Burden and Immune Cell Infiltration in Ovarian Cancer. (PubMed, Int J Mol Sci)
    Gene expression related to immune cell trafficking, inflammatory response, and immune response (z > 2.0) was significantly increased in SYNE1 mutated patients. SYNE1 mutation is associated with increased TMB and immune cell infiltration in ovarian cancer and may serve as an additional biomarker for immunotherapy response.
    Journal • Tumor mutational burden • IO biomarker • Immune cell
    |
    TMB (Tumor Mutational Burden) • SYNE1 (Spectrin Repeat Containing Nuclear Envelope Protein 1)
    |
    SYNE1 mutation
    over1year
    SYNE1 mutation is associated with increased tumor mutation burden and immune cell infiltration in ovarian cancer (SGO 2023)
    No abstract available
    Tumor mutational burden • Immune cell
    |
    TMB (Tumor Mutational Burden) • SYNE1 (Spectrin Repeat Containing Nuclear Envelope Protein 1)
    |
    SYNE1 mutation
    almost3years
    A novel genomic classification system of gastric cancer via integrating multidimensional genomic characteristics. (PubMed, Gastric Cancer)
    By integrating multidimensional genomic characteristics, we proposed a novel genomic classification system of GC associated with clinical phenotypes and provided a new insight to facilitate genome-guided risk stratification and disease management.
    Journal • Tumor Mutational Burden
    |
    HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • ARID1A (AT-rich interaction domain 1A) • CDH1 (Cadherin 1) • PREX2 (Phosphatidylinositol-3,4,5-Trisphosphate Dependent Rac Exchange Factor 2) • SYNE1 (Spectrin Repeat Containing Nuclear Envelope Protein 1)
    |
    TP53 mutation • TMB-H • HER-2 amplification • PIK3CA mutation • HER-2 mutation • ARID1A mutation • SYNE1 mutation